SynthesisClinical oral investigations2019
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Synthesis in Clinical oral investigations, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Drug induced hyperpigmentation: systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review.Cancers · 2025Review
- Imatinib mesylate promotes melanogenesis through the modulation of p38 and MITF in murine cells.Toxicological research · 2025Article
- Imatinib-induced hard palate mucosal discoloration in patients with gastrointestinal stromal tumour (GIST) and dermatofibrosarcoma protuberans (DFSP): a case series of three patients and literature review.Postepy dermatologii i alergologii · 2024Article
- Drug-Induced Pigmentation: A Review.Drugs · 2024Review
- Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.International journal of molecular sciences · 2023Review
- Medication related to pigmentation of oral mucosa.Medicina oral, patologia oral y cirugia bucal · 2022Review
- Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies.Journal of clinical medicine · 2021Review
- Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report.Clinical case reports · 2020Article
- Medication-Induced Oral Hyperpigmentation: A Systematic Review.Patient preference and adherence · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. MATERIALS AND
methodsA cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate.
resultsAmong the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants' mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation.
conclusionsThe development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. CLINICAL RELEVANCE: To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.